<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320345</url>
  </required_header>
  <id_info>
    <org_study_id>FAME0001</org_study_id>
    <secondary_id>ACTRN12611000249954</secondary_id>
    <nct_id>NCT01320345</nct_id>
  </id_info>
  <brief_title>The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.</brief_title>
  <acronym>FAME 1 EYE</acronym>
  <official_title>A Randomised Trial to Evaluate the Efficacy on Retinopathy and Safety of Fenofibrate in Adults With Type 1 Diabetes. A Multicentre Double-blind Placebo-controlled Study in Australia and Internationally.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sydney</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential benefits of 145 mg of daily&#xD;
      fenofibrate in adults with type 1 diabetes mellitus and pre-existing non-proliferative&#xD;
      diabetic retinopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes is the most common cause of adult onset blindness. Irreversible vision loss is a&#xD;
      most feared complication of diabetes. Fenofibrate is a blood fat lowering drug available in&#xD;
      Australia and has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%,&#xD;
      and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the&#xD;
      potential benefits of oral Fenofibrate 145mg once daily for average 36 months in 450 adults&#xD;
      with Type 1 diabetes mellitus who are at high risk of eye damage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2016</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of clinical significant retinopathy progression.</measure>
    <time_frame>As reported throughout the study and/or annual eye assessment post-randomisation</time_frame>
    <description>Comprising 2-step progression of ETDRS score (to at least moderately severe grade), clinically significant macular oedema, need for laser surgery, need for intraocular anti-VEGF or corticosteroid therapy or vitrectomy, adjudicated to be for diabetic retinopathy (DR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The individual components of the primary endpoint</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Clinically significant retinopathy progression, 2-step progression of ETDRS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinically significant macula oedema (CSME).</measure>
    <time_frame>As reported throughout the study</time_frame>
    <description>Occurrence of clinically significant macula oedema (CSME) per standard ophthalmological assessment or laser therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for laser surgery for DR</measure>
    <time_frame>As reported throughout the study</time_frame>
    <description>Need for laser surgery for DR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for intraocular anti-VEGF or corticosteroid injection or vitrectomy</measure>
    <time_frame>As reported throughout the study</time_frame>
    <description>Need for intraocular anti-VEGF or corticosteroid injection or vitrectomy for DR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Visual acuity using ETDRS/LogMar or Snellen Chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular volume and thickness</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Macular volume and thickness by Optical Coherence Tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation, the end of study visit (which is on average 36 months post-randomisation) and wash-out visit.</time_frame>
    <description>Albuminuria measured as urinary albumin:creatinine ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate.</measure>
    <time_frame>At study completion and washout visit</time_frame>
    <description>Estimated glomerular filtration rate using Modification of Diet in Renal Disease (MDRD) formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral neuropathy status</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Peripheral neuropathy status assessed by temperature &amp; vibration sensation and monofilament test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic neuropathy.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Autonomic neuropathy (QTc and R-R intervals) on annual ECGs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cardiovascular events.</measure>
    <time_frame>As reported throughout the study.</time_frame>
    <description>Total cardiovascular events including myocardial infarction, stroke, sudden cardiac death, hospitalisation for acute coronary syndrome or any revascularisation events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of foot ulcer and non-traumatic amputation.</measure>
    <time_frame>As reported throughout the study</time_frame>
    <description>Foot ulcer and/or non-traumatic amputation are reported by site during the study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lipid and lipoprotein levels</measure>
    <time_frame>At baseline and end of study</time_frame>
    <description>Lipid and lipoprotein levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers and molecular markers</measure>
    <time_frame>At baseline and end of study</time_frame>
    <description>Markers of inflammation, glycation and oxidative stress, angiogenesis and adipocyte function, and molecular markers, as change from baseline with study treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life questionnaire</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit</time_frame>
    <description>Quality of Life questionnaire completed by participants annually</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>145 mg tablet of fenofibrate administered daily for 36 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inert lactose tablet (otherwise matching active) administered daily for 36 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>145 mg tablet of fenofibrate administered once daily for 36 months.</description>
    <arm_group_label>Fenofibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inert lactose placebo</intervention_name>
    <description>Insert lactose tablet matching active tablet administered once daily for 36 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (for the main study):&#xD;
&#xD;
          1. Men or non-pregnant women (on acceptable contraception) with T1D* according to&#xD;
             standard criteria:&#xD;
&#xD;
               -  T1D defined as either (1) T1D diagnosed below 40 years of age and insulin therapy&#xD;
                  commencing within one year of T1D diagnosis, or (2) T1D diagnosed before, at or&#xD;
                  after 40 years of age along with: i) Documented history of ketoacidosis, and/or&#xD;
                  ii) Documented history of very low or undetectable C-peptide (fasting &lt;200 nmol/L&#xD;
                  or 0.2 pmol/L), and/or iii) Documented history of T1D related autoantibody/ies&#xD;
                  (anti-Glutamic acid decarboxylase, anti-A2, anti-ZnT8).&#xD;
&#xD;
          2. Age 18 years or over;&#xD;
&#xD;
          3. Estimated glomerular filtration rate (eGFR) must exceed 30 ml/min/1.73m2;&#xD;
&#xD;
          4. Must have at least one eligible eye with non-proliferative retinopathy (ETDRS score&#xD;
             35-53 inclusive) confirmed by current retinal photography within the last 3 months&#xD;
             (irrespective of prior laser therapy). Note: Any eye having undergone prior&#xD;
             pan-retinal laser therapy is not eligible, but prior focal, macular or grid laser does&#xD;
             not exclude that eye from eligibility.;&#xD;
&#xD;
          5. All types of insulin therapy, with no restriction by level of HbA1c;&#xD;
&#xD;
          6. Willing and able to comply with all study requirements, including treatment,&#xD;
             assessment and clinic visit attendances;&#xD;
&#xD;
          7. Able to personally read and understand the Participant Information and Consent Form&#xD;
             and provide written, signed and dated informed consent to participate in the study.&#xD;
&#xD;
        Eligibility criteria for the reference group is limited to age and gender matched&#xD;
        individuals who do not have T1D.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Definite indication for or contraindications to fibrate treatment (Other lipid drugs&#xD;
             [e.g. statins, ezetimibe, fish oils] are allowed.);&#xD;
&#xD;
          2. Need for bilateral intra-ocular treatment or laser photocoagulation therapy within the&#xD;
             next 3 months (this exclusion only applies to retinal laser photocoagulation treatment&#xD;
             to the posterior pole i.e. laser correction of corneas for short-sightedness is NOT an&#xD;
             exclusion criterion);&#xD;
&#xD;
          3. Prior bilateral pan-retinal photocoagulation (PRP) treatment for diabetic retinopathy;&#xD;
&#xD;
          4. Prior bilateral intra-ocular injection(s) within the last 6 months;&#xD;
&#xD;
          5. Bilateral cataract surgery within the last 6 months;&#xD;
&#xD;
          6. Planned bilateral cataract surgery within the next 12 months;&#xD;
&#xD;
          7. History of any other non-diabetic eye disease that is or is likely to affect bilateral&#xD;
             vision;&#xD;
&#xD;
          8. History of photosensitive skin rash or myositis;&#xD;
&#xD;
          9. Abnormal thyroid function (untreated);&#xD;
&#xD;
         10. Liver function tests exceeding 3x upper limit of normal (ULN);&#xD;
&#xD;
         11. Persistent elevated unexplained blood creatinine phosphokinase level above normal&#xD;
             range;&#xD;
&#xD;
         12. Documented fasting triglycerides (TG) levels &gt;6.5 mmol/L;&#xD;
&#xD;
         13. History of pancreatitis, deep vein thrombosis (DVT) or pulmonary embolism;&#xD;
&#xD;
         14. Use of investigational drugs in the prior 8 weeks;&#xD;
&#xD;
         15. Any unstable condition in last 3 months including active sepsis, diabetic&#xD;
             ketoacidosis;&#xD;
&#xD;
         16. Myocardial infarction (MI), unstable angina, stroke or heart failure within last 6&#xD;
             months;&#xD;
&#xD;
         17. Diagnosed cancer with ongoing treatment or prognosis anticipated at &lt;5 years;&#xD;
&#xD;
         18. Any obstacle to regular follow-up including scheduled clinic attendances;&#xD;
&#xD;
         19. Prior or planned organ transplantation (including islet cells) with subsequent&#xD;
             continued immunosuppression therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Keech, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHMRC Clinical Trials Centre, The University of Sydney</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alicia Jenkins, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHMRC Clinical Trials Centre, The University of Sydney</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liping Li</last_name>
    <phone>+61 2 9562 5000</phone>
    <email>fame1eye@ctc.usyd.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Canberra Hospital</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Shi</last_name>
      <email>Yi.Shi@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Stephen Twigg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace (Seo) Park</last_name>
      <email>seo.park@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Avinash Suryawanshi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Garvan Institute of Medical Research</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Richens</last_name>
      <email>r.richens@garvan.org.au</email>
    </contact>
    <investigator>
      <last_name>Jerry Greenfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Associates - South West Retina</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tania Tsang</last_name>
      <email>tania@retina.com.au</email>
    </contact>
    <investigator>
      <last_name>Gerald Liew</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunter Diabetes Centre</name>
      <address>
        <city>Merewether</city>
        <state>New South Wales</state>
        <zip>2291</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Rae</last_name>
      <email>maureen@hunterdiabetes.com.au</email>
    </contact>
    <investigator>
      <last_name>Claire Morbey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Doyle</last_name>
      <email>Jean.doyle@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Greg Fulcher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cairns Hospital</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Truelove-Hawkins</last_name>
      <email>Katherine.Truelove-Hawkins@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Ashim Sinha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Venita Bali</last_name>
      <email>venita.bali@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Anthony Russell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Healy</last_name>
      <email>Denise.Healy@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Chinmay Marathe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Adelaide Diabetes and Endocrine Services</name>
      <address>
        <city>Oaklands Park</city>
        <state>South Australia</state>
        <zip>5046</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Taylor</last_name>
      <email>pamela.taylor@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Stephen Stranks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barwon Health</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Chambers</last_name>
      <email>jo.chambers@barwonhealth.org.au</email>
    </contact>
    <investigator>
      <last_name>Mark Kotowicz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heidelberg Repatriation Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariam Hachem</last_name>
      <email>mariam.hachem@unimelb.edu.au</email>
    </contact>
    <investigator>
      <last_name>Elif Ekinci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baker Heart and Diabetes Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Boyle</last_name>
      <email>erin.boyle@baker.edu.au</email>
    </contact>
    <investigator>
      <last_name>Neale Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Kent</last_name>
      <email>sue.kent@unimelb.edu.au</email>
    </contact>
    <investigator>
      <last_name>David O'Neal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marika Bjorasen</last_name>
      <email>marika.bjorasen@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Peter Colman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fremantly Hospital</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Maxwell</last_name>
      <email>Sharon.Maxwell@uwa.edu.au</email>
    </contact>
    <investigator>
      <last_name>Tim Davis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lap Ying Ho</last_name>
      <email>lapyingho@cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Ronald Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland Diabetes Centre</name>
      <address>
        <city>Auckland</city>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tricha Ball</last_name>
      <email>TrichaB@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Manish Khanolkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prasanna Karunasekera</last_name>
      <email>Prasanna.Karunasekera@cdhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>Russell Scott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>New Zealand</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Retinopathy</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>Fenofibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

